Abstract: Disclosed is a single unit oral dosage form having, in combination, inositol and an extended release clonidine or extended release guanfacine. In one aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient the single unit oral dosage form. In another aspect, a method for treating ADHD and/or associated symptoms thereof includes administering to an ADHD patient inositol in combination with extended release clonidine or extended release guanfacine, whether administered separately or as a single dosage form.

Abstract: A method of treating, preventing, or delaying the progression of Type 1 diabetes mellitus by administering an effective amount of a fusion protein composition comprising a T-cell co-stimulation antagonist and a portion of an immunoglobulin molecule and an effective amount of a Type 1 diabetes autoantigen. The method includes, for example, administering a cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) molecule and a Type 1 diabetes autoantigen. Pharmaceutical compositions are also provided herewith.

Abstract: This invention relates to antibody-albumin nanoparticle complexes comprising albumin, an antibody with binding specificity for a cancer antigen (e.g. panitumumab), and paclitaxel, wherein the nanoparticle complex has been pre-formed in vitro such that the nanoparticle complex has antigen-binding specificity (e.g. EGFR binding specificity), for the purpose of providing cancer (e.g. EGFR-related cancer) treatments in a subject in need thereof.

Abstract: The invention relates to a conjugate of a protein or peptide with a therapeutic, diagnostic or labelling agent, said conjugate containing a protein or peptide bonding portion and a polyethylene glycol portion; in which said protein or peptide bonding portion has the general formula: in which Pr represents said protein or peptide, each Nu represents a nucleophile present in or attached to the protein or peptide, each of A and B independently represents a C1-4alkylene or alkenylene chain, and W? represents an electron withdrawing group or a group obtained by reduction of an electron withdrawing group; and in which said polyethylene glycol portion is or includes a pendant polyethylene glycol chain which has a terminal end group of formula —CH2CH2OR in which R represents a hydrogen atom, an alkyl group, or an optionally substituted aryl group. Also claimed are a method for making such a conjugate, and novel reagents useful in that method.

Abstract: A composition includes a pharmaceutical tablet dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a carrier matrix, a disintegrant, and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

Abstract: A composition includes a pharmaceutical dosage form configured to disintegrate in oral saliva and maintain a pH of 4 or less within the saliva during the time the dosage form is dissolving therein, the dosage form including a therapeutically effective amount of melatonin in a polymer carrier matrix and a sufficient amount of acid to impart the pH to the saliva, the amount of disintegrant being sufficient to cause the dosage form to completely disintegrate in the saliva within ten minutes from contacting the saliva.

Abstract: This disclosure provides progesterone formulations, methods of using these formulations, and their related pharmacokinetic parameters. In particular embodiments, the formulations disclosed herein allow for a reduction in the amount of progesterone administered to a patient in need thereof, while still providing the benefits of a larger dosage amount.

Abstract: (R)-12-hydroxystearic acid hydrazides as gelators and gels generated therefrom are provided. A series of (R)-12-hydroxystearic acid hydrazides produce gels that are self-standing and self-healing. The (R)-12-hydroxystearic acid hydrazides are capable of exhibiting gelling properties in a wide variety of solvents. The gels have demonstrated good potential for use in drug release.

Abstract: The presently disclosed subject matter provides a formulation for the use of 1-deoxygalactonojirimycin and/or enzyme replacement therapy for the treatment of Fabry disease.

Abstract: The present invention relates to a pharmaceutical composition that provides long-term stability of a hydrolytically labile antipsychotic agent

Abstract: The present invention relates to viral or cellular membrane coated nanostructures. Nanostructure networks, nanoscaffolds and articles of manufacture comprising the nanostructure, and uses thereof, are also provided. The present invention also relates to methods for anchoring, attaching and/or growing a target cell. Target cells, constituent(s) of the target cells, target substances made by the target cells or culture medium of the target cells prepared by the present methods, and uses thereof, are also provided.

Abstract: In situ gel-forming compositions are disclosed, which may comprise one or more absorbable polymers, solvents such as N-methyl-2-pyrrolidone, polyethylene glycol or DMSO, and one or more bioactive agents. The composition forms a hydrogel or semi-solid mass on contact with an aqueous environment. Methods of using in situ gel-forming composition for various applications are also disclosed.

Abstract: A material comprising a highly branched carbohydrate polymer, a polyalkylene glycol (or polyalkylene oxide) linked to the highly branched carbohydrate polymer, and a hydrophobic or amphiphilic group linked to the highly branched carbohydrate polymer and/or the polyalkylene glycol (or polyalkylene oxide), is described. Methods of making and using the material, as well as a soluble composition that contains the material and a hydrophobic solute compound, are also described.

Abstract: A composition including an immunostimulating RNA molecule in a dication containing solution wherein the RNA includes a chemical modification which is toxic to cancer or tumor cells. Pharmaceutical compositions incorporate the immunostimulating RNA with tumor cytotoxicity. Methods for treating cancer and tumors use the solution of the immunostimulating RNA with tumor cytotoxicity.

Abstract: The present invention relates to a novel long-acting palmitic acid-conjugated gonadotrophin-releasing hormone (GnRH) derivative and a pharmaceutical composition containing the same. A GnRH derivative of the present invention is expected to greatly contribute, through excellent bioavailability and increased half-life in blood, to the reduction in drug dosing frequency and dosage and the like in the treatment of sex hormone-dependent diseases. Particularly, the GnRH derivative can overcome the disadvantages of existing GnRH sustained-release preparations, which have the side effects of residual feeling and pain at the injection site.

Abstract: The present invention provides bifunctional compounds that efficiently dephosphorylate certain phospho-activated target proteins. Such target proteins can be any protein involved in the pathway of a disease or disorder, such as but not limited to cancer, neurodegeneration, metabolic disease, diabetes, insulin resistance, and so forth.

Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.

Abstract: Disclosed are compounds and compositions for the activation or induction of expression of a pattern recognition receptor (e.g., STING, RIG-I, MDA5), and methods of use thereof.

Abstract: Aspects of the disclosure provide compositions and methods for treating cancer characterized by surface expression of plectin-1. The disclosure relates, in part, to combinations of therapeutic agents (e.g., anti-plectin-1 antibodies and certain small molecules) that function together (e.g., synergistically) to inhibit cancer cell growth. In some embodiments, the disclosure relates to anti-plectin-1 antibody-drug-conjugates (ADCs).

Abstract: Provided herein are heavy chain constant regions (referred to as “modified heavy chain constant regions”), or functionally equivalent fragments thereof, that enhance biological properties of antibodies relative to the same antibodies in unmodified form. An exemplary modified heavy chain constant region includes an IgG2 hinge and three constant domains (i.e., CH1, CH2, and CH3 domains), wherein one or more of the constant region domains are of a non-IgG2 isotype (e.g., IgG1, IgG3 or IgG4). The heavy chain constant region may comprise wildtype human IgG domain sequences, or variants of these sequences. Also provided herein are methods for enhancing certain biological properties of antibodies that comprise a non-IgG2 hinge, such as internalization, agonism and antagonism, wherein the method comprises replacing the non-IgG2 hinge of the antibody with an IgG2 hinge.

Abstract: Provided are compositions and methods for treating cancer comprising the use of a immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy. The immunoconjugate in combination with a cytotoxic agent or cytotoxic therapy shows synergistic effects in cancer treatment.

Abstract: An embodiment of the present invention provides a nanocarrier in a micelle structure, a pharmaceutical composition for diagnosis of cancer, comprising the same nanocarrier, and a method for preparing the same nanocarrier. The nanocarrier is obtained by dispersing a water-in-oil nanoemulsion containing an oil phase ingredient, a surfactant, and an aqueous phase ingredient inclusive of a cancer cell fluorescence-inducing substance and a cancer cell-targeting polysaccharide in water to remove the oil phase ingredient, whereby the nanocarrier includes the aqueous phase ingredient.

Abstract: There is described a gene therapy approach for treating Wilson's disease in which a nucleic acid molecule is used which comprises a nucleotide sequence encoding for a functional ATP7B protein wherein the nucleotide sequence has at least 85% identity to the sequence of SEQ ID NO. 1. Also described are vectors comprising the nucleotide sequence and methods and uses thereof.

Abstract: The instant disclosure provides RNA-modulating agents that function to recruit one or more small regulatory RNA molecules (e.g., miRNA molecules, Y RNAs, and siRNAs) to a target mRNA thereby modulating (e.g., inhibiting) the translation of the target mRNA or destabilizing the mRNA. Also provided are miRNA inhibitors and diagnostic agents that have improved binding affinity for their target miRNAs. Methods for using the RNA-modulating agents, miRNA inhibitors and diagnostic agents are also provided.

Abstract: Nucleic acid constructs that allow insertion and/or expression of a sequence of interest, such as a transgene, are provided. Compositions and methods of using such constructs for expression of a polypeptide or therapeutic agent, for example, are also provided.

Abstract: The presently disclosed subject matter provides compositions and methods for the expression of CRISPR guide RNAs using the H1 promoter. In particular, compositions and methods are provided for the use of the H1 promoter to express CRISPR guide RNA (gRNA) with altered specificity of the 5? nucleotide, as well as use of the H1 promoter sequence as a bidirectional promoter to express Cas9 nuclease and the gRNA simultaneously. Compositions and methods are also provided for the expression and regulation of gRNA expression in vivo through the use of RNA ribozymes and regulatable aptazymes.

Abstract: The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of Rabies virus or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of Rabies virus infections. The present invention further describes a method of treatment or prophylaxis of rabies using the mRNA sequence.

Abstract: The present application discloses solid compositions for the oral administration of dyes, and diagnostic use thereof. Preferably, such diagnostic use is aimed at the diagnostic evaluation of the gastrointestinal tract.

Abstract: Described herein are peptides, compositions, and methods for diagnosing, detecting, imaging, monitoring, preventing, treating, or ameliorating diseases or disorders including cancer, inflammatory disorder, and autoimmune disease.

Abstract: Described herein is a method for detecting changes in blood flow in a tissue portion and/or body portion of an individual. The method can be used to detect any sort of pathology, trauma or insult which results in blood flow change. Specifically, this method uses hyperpolarized 129Xe MRI to detect xenon perfusion changes in tissues such as brain tissue that corresponds to changes in blood flow, for example, changes caused by functional activities of the brain or regions of the body where blood flow may be compromised.

Abstract: The purpose of the present invention is to provide composite particles for imaging that have high biodegradability after imaging. To achieve the above purpose, the composite particles for imaging according to the present invention are configured such that the ratio (long-term residual amount/short-term residual amount) of a long-term residual amount, which is the average value of the contrast rate after six days in a cell and the contrast rate after 11 days in a cell of the same type, and a short-term residual amount, which is the contrast rate after two days in a cell of the same type, is less than 99%.

Abstract: Described are: [1] a compound or the like represented by the formula (1); [2] a compound or the like having a target molecule recognition element bound to the compound or the like described in the above [1]; and [3] a metal complex compound or the like having a metal selected from the group consisting of a radioactive metal and a radioactive atom-labeled metal, and the compound or the like described in the above [1] or [2] coordinated to the metal. Also described are uses of the compound or the like described in the above [1] or [2] or the metal complex compound or the like described in the above [3] in a radioactive drug, a radiotherapeutic agent or a radioactive diagnostic imaging agent.

Abstract: There is provided a positron-emitting radionuclide labelled peptide for non-invasive PET imaging of the Urokinase-type Plasminogen Activator Receptor (uPAR) in humans. More specifically the invention relates to human uPAR PET imaging of any solid cancer disease for diagnosis, staging, treatment monitoring and especially as an imaging biomarker for predicting prognosis, progression and recurrence.

Abstract: Sanitizing surfaces comprising a sanitization device including a mobile body; and extending the sanitization device (102) laterally from the mobile body across a surface. A source of UV radiation (104) is mounted on the sanitization device. The sanitization device moves across the surface; exposing the surface to UV radiation produced by the source; directing a source of UV radiation to the surface at a predetermined dosage while the device moves over surface. Moving and locating the sanitization device can be inwardly and outwardly relative to the mobile body to extend at different angles being from a horizontal angle relative to the mobile body to a non-horizontal angle relative to the mobile body and to effect sanitization when so extended. The device is operable upwardly and downwardly across the surface while effecting the sanitation.

Abstract: To perform sterilization using a sterilization member that has a treatment surface that is a surface on which a plurality of protrusions each having a leading end that is thinner than a diameter of a microorganism that is to be killed are provided, a sterilization member on which each protrusion has a height that is greater than or equal to half the diameter of the microorganism that is to be killed is used as the sterilization member, and a fluid that contains the microorganism that is to be killed is caused to strike the treatment surface to kill the microorganism that is to be killed.

Abstract: To sterilize a sterilization filter unit with heated steam, minimize the heat load on the sterilization filter unit and extend the service life of the sterilization filter unit. Heated steam is supplied to a sterilization filter unit that sterilizes supplied air, the temperature of the heated steam discharged from the sterilization filter unit is measured at predetermined time intervals, the F value is calculated from the measured temperature, and sterilization of the sterilization filter unit is ended when the F value reaches a target value.

Abstract: The purpose of the present invention is to provide an ultraviolet sterilization device that can increase the ultraviolet irradiance near the center of a treatment flow path even at a position far from a light emitting element. This ultraviolet sterilization device comprises: a flow path tube having a linear treatment flow path therein; a light emitting element for emitting ultraviolet rays; and a reflector having a reflection surface for reflecting ultraviolet rays emitted from the light emitting element and collecting and directing the ultraviolet rays to the flow path tube. The ultraviolet sterilization device irradiates a fluid flowing in the linear treatment flow path with ultraviolet rays and sterilizes the fluid.

Abstract: In a system and method for disinfecting a surface of an object with iodine-laden gas, a carrier gas generation means generates a gas stream, which is then directed into a chamber that includes an iodine source. As the gas stream enters and passes through the chamber, iodine is drawn and absorbed into the gas stream, creating an iodine-laden gas that exits the chamber. The carrier gas stream is humidified prior to or after its interaction with the iodine source. In some embodiments, the iodine-laden gas then travels from the chamber and is directed into an enclosure when it interacts with microbes contained on a surface of an object housed within the enclosure or otherwise engaged by the enclosure. In other embodiments, as the iodine-laden gas exits the chamber, it is directed to a nozzle, via which the iodine-laden gas is applied to the surface of the object to be disinfected.

Abstract: A sterile container includes a container pan, a container cover, a closure for closing the sterile container, and a seal or sealing element between the container pan and the container cover. The seal or sealing element is vapor-permeable.

Abstract: A system includes a disinfection chamber having an interior volume, a radiation source to emit radiation into the interior volume, a radiation sensor circuit to detect radiation in the interior volume, an independent monitoring circuit to detect radiation in the interior volume, and a computing device that has a memory and a processor. The memory stores first radiation values captured by the radiation sensor circuit, second radiation values captured by the independent monitoring circuit, and computer instructions. The processing unit executes the computer instructions to start the emission of radiation, generate first and second accumulated radiation values from the stored values, respectively, and stop the emission of radiation after reaching a first radiation threshold. Based on a comparison of the first accumulated radiation value to the second accumulated radiation value, a validated disinfection signal or an error signal will be asserted.

Abstract: Sterilization packaging systems with features for sealing a volume against an ingress of contaminants are provided. Such features include a sealing assembly including a gasket and a sheet of filter material. The sealing assembly seals a lid to a seal rim of a base. The gasket has an upper surface, outer edge, and inner edge. The upper surface of the gasket comprises a first row of alternating protrusions and indentations and a second row of alternating protrusions and indentations that define a channel therebetween. The sheet of filter material extends from an inner edge of the gasket. The gasket completely surrounds the sheet of filter material, wherein the indentations and channel facilitate delivery of a sterilization agent through the filter material. A sterilization assembly including a lid having a plurality of protrusions in its upper surface in conjunction with a gasket having a smooth upper surface is also provided.

Abstract: A scent diffusing device having a first housing connected to a second housing and adapted to provide electrical power to a heating element disposed within the second housing. A cap assembly is removably attached to the second housing. The cap assembly has a support member removably attached to a cover, and a fragrance emitting member removably received within the support member. The support member has a central hollow tube that slidably receives the heating element.

Abstract: An ergonomic scent diffuser having a first housing with electrical components connected to a second housing having a heating element disposed within. Slidably connected to the second housing is a cap. The cap has depressions adjacent an outer end to provide an ergonomic grip. The cap also has guide rails and retaining members that retain and position a fragrance emitting member over the heating element.

Abstract: A portable air freshener device that inhibits the release of fragrance when the fan is not being operated, and that controls operation of the fan based at least in part on ambient temperature in some embodiments.

Abstract: A siphon type essence diffuser having block-preventing and leakage-preventing capabilities includes an outer shell and a universal atomizer connector contained therein. The universal atomizer connector is of a tube shape formed integrally into a body, having a first end connectable to the bottle port of an essence oil container presently available on the market. A nozzle cover and an atomized plate are disposed on the tube port of the second end. An essence supply channel is disposed between the first end and the second end. A siphon essence oil supply mechanism is disposed on universal atomizer connector, with one end of a cotton rod pressing against a back side of the atomized plate, and with the other end of a cotton rod extending into the essence oil supply channel to absorb essence oil.

Abstract: An air cleaning apparatus includes: a collection filter for collecting dust; a first ultraviolet light emitter for irradiating the collection filter with ultraviolet light having a first wavelength; and a photocatalyst supporting filter which supports a photocatalyst exhibiting photocatalytic activity by the ultraviolet light having the first wavelength and collects the dust. The collection filter transmits the ultraviolet light having the first wavelength, and the ultraviolet light having the first wavelength passing through the collection filter is irradiated to the photocatalyst supporting filter.

Abstract: A disinfection system of a contact lens comprising immersing the contact lens in a disinfecting solution containing hydrogen peroxide in a concentration of 1 to 10% and neutralizing the hydrogen peroxide in the disinfecting solution through contact with a metal catalyst, where the disinfecting solution contains an organic carboxylic acid or a salt of the organic carboxylic acid, the organic carboxylic acid having a structure in which a hydroxyl group and a carboxyl group are bonded to one carbon atom; the disinfecting solution is adjusted to have a pH of 6 to 8; and the disinfecting solution after the neutralization is adjusted to have an osmotic pressure of 250 to 350 mOsm.

Abstract: Disclosed are settable bone cements incorporating silicon nitride in various forms as a component, including powders, granules, particulates, portions, layers and/or coatings of solids and/or particulates of silicon nitride and/or components thereof, that may be useful in joint and/or bone replacement implants used in spinal surgeries, dental surgeries and/or other orthopedic and/or general surgical procedures.

Abstract: A magnesium phosphate bone cement includes a powder agent and a liquid agent. A liquid-to-solid ratio of the liquid agent to the powder agent is 0.1-0.5 ml/g. The powder agent comprises following components: phosphate accounting for 32-70 wt %, magnesium oxide accounting for 28-65 wt %, and silicon-containing compound accounting for 1-15 wt %. Preferably, the powder agent further comprises ammonium dihydrogen phosphate, and degradable and adhesion-promoting material, wherein the ammonium dihydrogen phosphate accounts for 5-30 wt % of a total weight of the phosphate.

Abstract: Provided is a non-tubular brain damage recovery material which is used to cover and/or fill a damaged part of the brain, the brain damage recovery material including: (A) a cross-linked body with which a bioabsorbable polysaccharide having a carboxyl group in a low endotoxin molecule is covalently bonded and cross-linked with at least one crosslinking reagent selected from among a compound represented by general formula (I) and salts thereof; and (B) a bioabsorbable polymer. R1HN—(CH2)n—NHR2 (I) [in the formula, R1 and R2 each independently represent a hydrogen atom or a group represented by formula of —COCH(NH2)—CH2]4—NH2, and n represents an integer from 2 to 18]. Accordingly, provided is a medical material which can recover a damaged part of the brain.